Archbow

https://www.pharmaceuticalcommerce.com/pe_w/questions

Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. As manufacturers prepare for launch, they must sort through and choose third-party organizations that can help support their efforts: 3PL organizations, distribution partners, pharmacies, HUB providers, serialization partners, data analytics, and more. Getting answers to these eleven key questions will help guide commercial teams in effectively launching specialty products.

Identify the types of third-party organizations that can help support your specialty drug launch

Understand the key considerations and composition of establishing third-party partnerships

Determine the difference between having greater access or greater control, and how that can impact the commercial success of your launch

CEOs and Chief Commercial Officers at emerging biotechs

Directors and VPs of Brand Management or Marketing

Directors and VPs of Trade and Distribution


Vice President

With over 20 years of pharmaceutical supply chain experience, Rob Besse has an established track record of collaborating with leaders of specialty pharmaceutical manufacturing, consulting, and wholesaling. He's aided in the launch of almost 100 new drugs and enhanced existing product programs, primarily in the physician and clinic space. His diverse career allows him to provide a unique insider perspective, offering creative solutions related to selecting a launch channel strategy, contracting with distributors, wholesalers, 3PLs, data and EDI requirements, program pricing, REMS logistics, rebate programs, compliance concerns, and changes to commercialization strategy.Prior to joining Archbow, Rob served as Vice President, Operations at Besse Medical, part of the AmerisourceBergen Corporation. He was responsible for business development, procurement, contracting, compliance, and overall divisional operations. He served in that role from 1998 to 2018 and was part of the management team that grew that division into a multi-billion dollar organization during that timeframe. Rob has a bachelor’s degree in pharmacy from The Ohio State University and is still a licensed pharmacist in Ohio.

Articles

Wednesday, October 5, 2022, 11am EDT
Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. Get answers to eleven key questions that will help guide commercial teams in effectively launching specialty products.